A new feature in Chemical & Engineering News ↗, summarized in this week's peptide news digest, takes the cleanest look yet at whether the amylin class can carve real share in an obesity market dominated by Wegovy ↗ and Mounjaro ↗. The framing is direct: two years ago, amylin analogs were Wall Street's preferred GLP-1 successor story. Phase 2 readouts have arrived, and the differentiation has not.
Amylin is a separate gut hormone from GLP-1, secreted alongside insulin and acting on the calcitonin-amylin receptor complex (the CALCR/RAMP ↗ system). The only FDA-approved amylin drug is Pramlintide / Symlin, used in diabetes since 2005. The new generation of obesity candidates redesigns amylin into longer-acting analogs that can be given alongside GLP-1 drugs or as standalone weekly injections.
Three programs lead. Novo Nordisk's cagrilintide ↗, already part of the company's CagriSema co-formulation with semaglutide ↗, is the most clinically advanced. Eli Lilly's eloralintide is in mid-stage development. Roche/Zealand's petrelintide ↗ is the long-shot of the three. Each is positioned to fix one or both of the GLP-1 class's main downsides: lean-mass loss during rapid weight reduction, and the gastrointestinal side effects that drive a meaningful percentage of patients off therapy within the first year.
Phase 2 has not delivered the differentiation early investors had assumed. Wall Street initially expected amylin candidates to differentiate from semaglutide and tirzepatide ↗ on muscle preservation and reduced GI side effects. The readouts have not delivered that profile cleanly enough to support a class-level repositioning, and analyst enthusiasm has cooled accordingly. CagriSema's Phase 3 head-to-head against tirzepatide is the readout that decides the case. If a GLP-1 plus amylin combination beats the leading dual-agonist on either weight loss or body composition, the amylin story re-opens. If it does not, amylin obesity becomes a niche category for patients who cannot tolerate GLP-1 alone.
Two pieces of context worth holding. First, Pramlintide (Symlin), the existing amylin drug, has always sat in a clinical corner of diabetes care. It works, but it is injected three times a day with meals, requires titration to avoid hypoglycemia, and never reached blockbuster status. The new candidates fix the dosing problem with weekly injection. Whether they fix the share problem depends on whether obesity patients see a reason to choose them over what is already in the pharmacy.
Second, this question matters beyond Roche, Lilly, and Novo. The amylin case is a stress test for the broader thesis that GLP-1 is one node in a multi-hormone obesity-control system, not the single lever. If amylin layered on top of GLP-1 does not produce more, the next wave of dual or triple agonists (GLP-1 plus glucagon, GLP-1 plus GIP, GLP-1 plus amylin plus glucagon) gets harder to justify on biology alone. Each program then has to win on commercial grounds, not class economics.
The CagriSema readout will land in a crowded calendar. Lilly Q1 prints April 30. Novo Q1 prints May 6. Foundayo's slow launch is already reframing the GLP-1 retail pricing case. The amylin verdict arrives into a market that has more pricing pressure than story, and will need to clear a higher bar than early-phase enthusiasm assumed.